Circulating tumor cells (CTCs) are an early warning sign of cancer
Starting at the beginning of a tumor’s growth, a very small number of cancer cells detach from the tumor and enter the bloodstream. These rare tumor cells circulate amidst trillions of blood cells. Appearing years before the disease spreads, circulating tumor cells (CTCs) act as a sentinel of cancer in the earliest days of tumor development. Some of them may become the seeds of metastases. ISET’s unparalleled sensitivity detects these very first CTCs and alerts for the presence of a tumor or tumor recurrence.
As the building blocks of the tumor, CTCs also contain the most complete information about a patient’s cancer. These cells provide “real-time” information about genetic and protein mutations of tumors. CTC-DNA, extracted from the very first sentinel CTCs isolated by ISET, allows for the detection of tumor DNA in blood at the earliest stages of cancer development and, when combined with information from ctDNA, provides the most sensitive tumor DNA detection through comprehensive liquid biopsy.
Our technology is designed to detect cancer earlier
Rarecells’ proprietary ISET® (Isolation by Size of Tumor cells) device is a highly accurate, non-invasive liquid biopsy technology, designed to detect cancer earlier and prevent metastases.
ISET® extracts Circulating Tumor Cells (CTCs) from the blood using a powerful size-based isolation system, keeping CTCs intact and ready for downstream analyses. ISET© also extracts circulating giant cells and tumor cell clusters (micro-emboli) from blood, without loss.
Rarecells’ device is a certified CE-Mark In Vitro Diagnostic (CE-IVD) with the demonstrated unparalleled ability to extract down to a single cancer cell from among 50 billion blood cells in a 10 ml blood sample.
Rarecells’ early detection cancer tests leverage AI-powered analyses of intact CTCs isolated by ISET, including immunomorphological profiles and CTC-DNA (methylation analysis and NGS). This provides valuable insights with the potential to treat cancer years ahead of a current typical diagnosis.
ISET® combines CTC-DNA and ctDNA analysis, overcoming sensitivity challenges in using ctDNA for early-stage cancer detection and providing a more reliable screening solution.
A strong base of published evidence
ISET®’s unparalleled sensitivity and specificity have been established through 110+ high-level, peer-reviewed and independent scientific publications. ISET® has proven its clinical value in studies with more than 3,400 patients and 1,200 healthy subjects as controls for virtually all types of solid tumors and the main types of leukemia. Studies demonstrated the efficacy and utility of tests using ISET®-collected cells in early detection of cancer, cancer prognosis, and non-invasive theranostics.
0
TYPES OF CANCER
0
+
CLINICAL STUDIES
0
K+
STUDY SUBJECTS